sulfinpyrazone has been researched along with 2019 Novel Coronavirus Disease in 1 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abo Elmaaty, A | 1 |
| Hamed, MIA | 1 |
| Ismail, MI | 1 |
| B Elkaeed, E | 1 |
| S Abulkhair, H | 1 |
| Khattab, M | 1 |
| Al-Karmalawy, AA | 1 |
1 other study available for sulfinpyrazone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Auranofin; Binding Sites; Computational B | 2021 |